HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Marta Milo Selected Research

Inflammation (Inflammations)

3/2011Prolyl hydroxylase 3 (PHD3) is essential for hypoxic regulation of neutrophilic inflammation in humans and mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Marta Milo Research Topics

Disease

3Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease)
10/2021 - 01/2017
2Disease Progression
01/2017 - 11/2009
2Hypoxia (Hypoxemia)
02/2015 - 03/2011
2Deafness (Deaf Mutism)
10/2012 - 01/2010
2Neoplasms (Cancer)
03/2010 - 11/2009
1Ototoxicity
01/2018
1Neurodegenerative Diseases (Neurodegenerative Disease)
01/2017
1Ganglion Cysts (Ganglion)
12/2015
1Mitochondrial Diseases (Mitochondrial Disease)
12/2013
1Inflammation (Inflammations)
03/2011
1Myeloproliferative Disorders (Myeloproliferative Disorder)
03/2010
1Hearing Loss (Hearing Impairment)
01/2010
1Cardiovascular Diseases (Cardiovascular Disease)
01/2010
1Urinary Bladder Neoplasms (Bladder Cancer)
11/2009
1Carcinogenesis
11/2009

Drug/Important Bio-Agent (IBA)

4MicroRNAs (MicroRNA)IBA
01/2017 - 11/2009
2Insulin-Like Growth Factor I (IGF-1)IBA
12/2015 - 01/2010
1Nuclear RNAIBA
10/2021
1Superoxide Dismutase-1IBA
09/2018
1ResveratrolIBA
01/2018
1SolutionsIBA
01/2018
1Furosemide (Lasix)FDA LinkGeneric
01/2018
1KanamycinFDA Link
01/2018
1Acetylcysteine (Siran)FDA LinkGeneric
01/2018
1Biomarkers (Surrogate Marker)IBA
01/2017
1Phosphotransferases (Kinase)IBA
12/2013
1Oxygen (Dioxygen)IBA
03/2011
1Prolyl Hydroxylases (Prolyl Hydroxylase)IBA
03/2011
1Small Interfering RNA (siRNA)IBA
03/2010
1Janus KinasesIBA
03/2010
1Karyopherins (Importin)IBA
11/2009

Therapy/Procedure

4Therapeutics
10/2012 - 11/2009